Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial
(RTTNews) - Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company, announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer